# Lanreotide Autogel for persistent diabetic macular edema.

> PubMed lists PMID 18367285 in Diabetes research and clinical practice as Case Reports, Journal Article, with publication-date metadata of 2008-03-26 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18367285-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18367285-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-18367285-lanreotide-v1.json
- Content SHA-256: `7b39584fe1306173b2dc78af59203d221b53a7ea4165903321b1d3c2c4681027`

## Claims and source pins

### Headline

Lanreotide Autogel for persistent diabetic macular edema. ([`pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9`](#source-pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9))

### Summary

PubMed lists PMID 18367285 in Diabetes research and clinical practice as Case Reports, Journal Article, with publication-date metadata of 2008-03-26 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9`](#source-pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9))

### Paragraph 1

PubMed lists PMID 18367285 in Diabetes research and clinical practice as Case Reports, Journal Article, with publication-date metadata of 2008-03-26 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9`](#source-pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9`](#source-pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9))

## Sources

<a id="source-pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9"></a>
- **Lanreotide Autogel for persistent diabetic macular edema. · retained source version 1:2016-11-24:current:4f30b93e4eb99070c75306400e4ab9a950610c47a7e7be896061dbc9340657c2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18367285/) (`pubmed-observation-pmid-18367285-2016-11-24-4f30b93e4eb9`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Lanreotide Autogel for persistent diabetic macular edema." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-18367285-lanreotide-v1.json SHA-256: 7b39584fe1306173b2dc78af59203d221b53a7ea4165903321b1d3c2c4681027.